Drug Profile
Research programme: epilepsy gene therapy - Neurologix
Alternative Names: NLX E201Latest Information Update: 09 Jun 2014
Price :
$50
*
At a glance
- Originator Neurologix
- Class Gene therapies
- Mechanism of Action Neuropeptide Y receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Temporal-lobe-epilepsy
Most Recent Events
- 16 Mar 2012 Discontinued - Preclinical for Temporal lobe epilepsy in USA (Intracerebral)
- 16 Mar 2010 Preclinical development is ongoing in USA
- 01 Oct 2004 Preclinical trials in Temporal lobe epilepsy in USA (Intracerebral)